Introduction
============

The prevalence of carbapenem-resistant isolates of *Acinetobacter baumannii*is increasing in Tunisian ICUs. The wide use of antibiotherapy is implicated certainly in this mechanism of resistance.

Objective
=========

The purpose of this study is to evaluate the evolution of *A. baumannii*resistance after a new strategy of prescription consisting of controlling and restriction of antibiotherapy prescription.

Materials and methods
=====================

Evolution of resistance of all *A. baumannii*isolates is compared between 2001 (before antibiotherapy restriction) and 2003--2004 (after).

Results
=======

See Table [1](#T1){ref-type="table"}.

  \% of resistance   2001 (*n*= 134)   2003 (*n*= 50)   *P*      2004 (*n*= 63)   *P*\'
  ------------------ ----------------- ---------------- -------- ---------------- --------------
  Ticarcilline       76                63               0.05\*   77               0.8
  Piperacilline      97                85               0.01\*   81               10^-3^\*
  Ceftazidim         95                84               0.01\*   79               8 × 10^-4^\*
  Carbapenem         37                37               0.36     25               0.09
  Amikacine          85                70               0.28     68               6 × 10^-3^\*
  Netilmycine        30                31               0.86     31               0.7
  Ofloxacine         95                87               0.04\*   93               0.9
  Ciprofloxacine     95                87               0.16     94               0.9

*P*, 2003 -- 2001; *P*\', 2004 -- 2001. \**P*\< 0.05.

Conclusion
==========

With antibiotherapy restriction we have obtained a significant reduction of resistance for piperacillin, ceftazidim and amikacin. We have obtained also a decrease of carbapenem-resistant isolates (37% vs 25%) but not significant enough if compared with other countries (5% in New York and 11% in Brazil).
